- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05738187
Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study (CRYORL)
In France, squamous cell carcinomas of the head and neck (SCCHN) are the 5th most common cancer. 60% of patients present with locally advanced tumors (stage III/IV), characterized by a poor prognosis (5-year survival not exceeding 60%). The standard treatment consists of either surgical removal followed by adjuvant radiochemotherapy or exclusive radiochemotherapy.
In case of locoregional recurrence (about 40% of patients), salvage surgery can be proposed, allowing prolonged survival for less than one third of eligible patients. However, more than half of locoregional recurrences are unresectable. The standard treatment then consists of immunotherapy and/or chemotherapy for palliative purposes with a median survival of no more than 15 months. Stereotactic radiotherapy is another potentially curative option that allows a local control of 30-60% at 1 year, but at the cost of significant toxicity (up to 50% of grade 3-4 toxicities), thus limiting its indication.
The issue of salvage treatment also applies to other rarer histological forms, including naso-sinus and salivary gland tumors, for which the probability of overall survival at 5 years does not exceed 65% due to locoregional evolution, despite advances in surgical techniques and the addition of radiotherapy.
During the last two decades, minimally invasive interventional radiology techniques have been developed in the field of oncology. Among these techniques, cryotherapy is now commonly used for the treatment of several cancers. The multiplication of its indications is based on numerous clinical advantages (good post-operative analgesia, good toxicity profile, good tumor control). Cryotherapy could thus be a therapeutic alternative in head and neck cancers in recurrence situation in irradiated and unresectable territory, allowing to maintain a curative project in a higher proportion of patients and also to have a more favorable toxicity profile than re-irradiation.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Luigi Roberto CAZZATO, MD
- Phone Number: 0033 03 69 55 16 35
- Email: roberto-luigi.cazzato@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67000
- Hôpitaux Universitaires de Strasbourg
-
Contact:
- Luigi Roberto CAZZATO, MD
- Phone Number: 0033 03 69 55 16 35
- Email: robertoluigi.cazzato@chru-strasbourg.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Malignant head/neck tumor
- Unresectable locoregional recurrence in a previously irradiated area
- Contraindication to re-irradiation
- Age > 18 years
- Performance index ≤ 2 (WHO)
- Life expectancy > 12 weeks
- Absence of hemostasis disorders
- Renal function: creatinine clearance ≥ 30 mL/min by CKD-EPI method (Cockcroft-Gault formula or MDRD)
- Subject affiliated to a social security health insurance plan
- Subject able to understand the objectives and risks of the research and to give dated and signed informed consent
- For a woman of childbearing age, negative blood pregnancy test at the inclusion visit
Exclusion Criteria:
- Stage IV with distant metastases or multiple tumors
- Melanoma, sarcoma, and lymphoma
- Participants who have received chemotherapy or radiation therapy within 4 weeks
- Other active cancer within the past 2 years (patients with carcinoma in situ, papillary thyroid carcinoma, basal cell skin carcinoma, localized Gleason 6 prostate cancer, or breast cancer in situ are allowed)
- Concomitant therapy with any other systemic anticancer treatment
- Contraindication of anaesthesiology character
- Contraindication to MRI
- Participation in another clinical study
- Any social, medical or psychological condition that may prevent the patient from complying with the constraints of the protocol
- Any significant pathology that may interfere with the patient's participation in the study
- Subject under court protection
- Subject under guardianship or curatorship
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: local cryotherapy treatment
|
cryotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local tumour control rate
Time Frame: at 12 months
|
Tumour control is defined as no increase in size and no suspicious contrast (or radiotracer) in the ablation area.
Any suspected recurrence on cross-sectional imaging will be confirmed by biopsy.
|
at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local tumour control rate
Time Frame: at 6 months post-procedure
|
Tumour control is defined as no increase in size and no suspicious contrast (or radiotracer) in the ablation area.
Any suspected recurrence on cross-sectional imaging will be confirmed by biopsy.
|
at 6 months post-procedure
|
Rate of complications/adverse events (including serious) possibly related to cryotherapy
Time Frame: at 12 months
|
assessed by the NCI-CTCAE severity scale version 5.0
|
at 12 months
|
To evaluate the quality of life of patients
Time Frame: at 1, 3, 6 and 12 months after cryotherapy
|
Scale EORTC-QLQ-C30
|
at 1, 3, 6 and 12 months after cryotherapy
|
To evaluate the quality of life of patients
Time Frame: at 1, 3, 6 and 12 months after cryotherapy
|
Scale EORTC - QLQ - H&N35
|
at 1, 3, 6 and 12 months after cryotherapy
|
To evaluate the quality of life of patients
Time Frame: at 1, 3, 6 and 12 months after cryotherapy
|
Scale VHI 10
|
at 1, 3, 6 and 12 months after cryotherapy
|
To evaluate the quality of life of patients
Time Frame: at 1, 3, 6 and 12 months after cryotherapy
|
Scale MDADI_v1.0
|
at 1, 3, 6 and 12 months after cryotherapy
|
To evaluate the quality of life of patients
Time Frame: at 1, 3, 6 and 12 months after cryotherapy
|
Scale DHI
|
at 1, 3, 6 and 12 months after cryotherapy
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8761 (CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Cancer
-
UNICANCERCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerFrance
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerChina
-
Merck Sharp & Dohme LLCCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck CancerUnited States
-
Royal Marsden NHS Foundation TrustRecruitingRecurrent Head and Neck CancerUnited Kingdom
-
Rakuten Medical, Inc.CompletedRecurrent Head and Neck CancerUnited States
-
University of Colorado, DenverCompletedRecurrent Head and Neck CancerUnited States
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
AmgenCompletedRecurrent and/or Metastatic Head and Neck Cancer
Clinical Trials on local cryotherapy treatment
-
Guangzhou Medical UniversityNingbo SensCure Biotechnology Co., Ltd.Recruiting
-
The 306 Hospital of People's Liberation ArmyNot yet recruiting
-
Blackwell Device ConsultingEmblation LimitedRecruiting
-
Fondation IldysLille Catholic UniversityRecruitingMultiple SclerosisFrance
-
CooperSurgical Inc.Completed
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Cairo UniversityNot yet recruiting
-
Creighton UniversityCompleted
-
Hanyang University Seoul HospitalCompletedCryotherapy EffectKorea, Republic of
-
Ondokuz Mayıs UniversityRecruitingPain, Postoperative | Pulpitis | Caries; DentinTurkey